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General cognitive function is substantially heritable across the human life course from adolescence to old age. We investigated the
genetic contribution to variation in this important, health- and well-being-related trait in middle-aged and older adults. We
conducted a meta-analysis of genome-wide association studies of 31 cohorts (N= 53 949) in which the participants had undertaken
multiple, diverse cognitive tests. A general cognitive function phenotype was tested for, and created in each cohort by principal
component analysis. We report 13 genome-wide signiﬁcant single-nucleotide polymorphism (SNP) associations in three genomic
regions, 6q16.1, 14q12 and 19q13.32 (best SNP and closest gene, respectively: rs10457441, P= 3.93 × 10− 9, MIR2113; rs17522122,
P= 2.55 × 10− 8, AKAP6; rs10119, P= 5.67 × 10− 9, APOE/TOMM40). We report one gene-based signiﬁcant association with the HMGN1
gene located on chromosome 21 (P= 1× 10− 6). These genes have previously been associated with neuropsychiatric phenotypes.
Meta-analysis results are consistent with a polygenic model of inheritance. To estimate SNP-based heritability, the genome-wide
complex trait analysis procedure was applied to two large cohorts, the Atherosclerosis Risk in Communities Study (N= 6617) and
the Health and Retirement Study (N= 5976). The proportion of phenotypic variation accounted for by all genotyped common SNPs
was 29% (s.e. = 5%) and 28% (s.e. = 7%), respectively. Using polygenic prediction analysis, ~ 1.2% of the variance in general
cognitive function was predicted in the Generation Scotland cohort (N= 5487; P= 1.5 × 10− 17). In hypothesis-driven tests, there was
signiﬁcant association between general cognitive function and four genes previously associated with Alzheimer’s disease: TOMM40,
APOE, ABCG1 and MEF2C.
Molecular Psychiatry (2015) 20, 183–192; doi:10.1038/mp.2014.188; published online 3 February 2015
INTRODUCTION
The systems with which humans face the challenges of the
external and internal environments tend to show deterioration in
their mean level of efﬁciency as people age. For example, the
immune system,1 cardiovascular2 and respiratory systems,3 renal
function4 and stress responses5 are, on average, not as efﬁcient in
old age as they were in young adulthood. When met with a
challenge to a system, healthy older people tend to have a
reduced reserve capacity compared with younger adults. The
nervous system also declines, with sensory function6,7 and motor
strength and co-ordination8 not at their highest mean level in
older age.
The brain’s cognitive functions show a heterogeneity of age-
related changes. Some capabilities such as vocabulary, some
number skills and general knowledge withstand the aging trend
and tend (in the absence of neurological disease) to remain intact
into older age, although they decline eventually.9–11 These
cognitive functions, which rely on the access to stored informa-
tion, are called crystallized abilities.12
By contrast, ﬂuid cognitive abilities, which rely on on-the-spot
information processing, show more age-related decline in mean
levels.9–14 Through ﬂuid cognitive abilities, the brain equips us to,
for example, recognize and recall previously unseen stimuli, and to
make associations between previously unrelated stimuli (mem-
ory); induce general rules from sets of occurrences and to apply
these rules to new situations (reasoning); perform simple,
repetitive cognitive tasks accurately and at high speed (processing
speed); compute mental two- and three-dimensional transforma-
tions of objects and locations (spatial ability); and organize
thinking (executive functioning). By comparison with crystallized
abilities, tests of ﬂuid cognitive abilities tend to employ unfamiliar
and often abstract materials, and draw less on stored knowledge,
education and broader enculturation. Each domain of ﬂuid
cognitive ability is important and is a major object of research
in its own right.15,16 However, when taken together the cognitive
domains show an interesting regularity. If we apply a number of
cognitive tests that assess diverse cognitive functions to a large
and varied sample, the correlations are universally positive; people
who tend to do well on one domain of ﬂuid cognitive ability tend
to do well in all of the others, although the associations are far
from perfect.17 This means that some of the observed inter-
individual variation in any single cognitive domain can be
attributed to at least four sources: how good they are generally
at all ﬂuid cognitive tests, how good they are at that ﬂuid
cognitive domain, how good they are at speciﬁc tests within any
one domain, and error of measurement.18
In the present study, we focus on the variance that crosses a
number of different ﬂuid cognitive functions, that is, on general
ﬂuid cognitive ability. We examine the genetic contributions to
this ability in middle and older age. There are good reasons for
doing so. General cognitive ability remains a strong source of
cognitive variation in older age, probably accounting for about as
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much cognitive variation as in young adulthood.19 General cogni-
tive function accounts for a substantial proportion of the age-
related variance9,20and genetic variance21,22 of people’s cognitive
test differences in middle and older age. Across adulthood, and
especially in older age, lower ﬂuid cognitive ability and greater
decline in it across the life course are associated with earlier
mortality.23–25 It can also be argued that if mean levels of ﬂuid
cognitive tests show decline with age, then people’s differences in
cognitive functions become more important as they grow older,
because the levels of cognitive functioning that remain in older
age are nearer to the critical levels that are needed for everyday
functions.26
To date, behavior genetic research—using twin, adoption and
family designs—shows that general cognitive ability is substan-
tially heritable across the life course, from late childhood to old
age.22 The heritability of general cognitive functioning in old age
might decrease slightly from its levels in young and middle
adulthood. Candidate gene studies have found that variation in
APOE genotype is the only reliable individual genetic associate of
cognitive function in older age, but that might apply especially to
cognitive change rather than cognitive level in old age.27–29 Using
the genome-wide complex trait analysis procedure (GCTA),
genome-wide association studies (GWAS) found that ~ 51% (the
s.e. was large, at 11%) of the variation in general ﬂuid cognitive
function in late middle age and older age could be accounted for
by genetic variation that is tagged by single-nucleotide poly-
morphisms (SNPs) on the Illumina610-Quadv1 chip.30 That study
was conducted in a total discovery sample of 3511 individuals,
with replication in 670 independent individuals. It found no
genome-wide signiﬁcant single SNP associations. From other
GWAS studies of complex traits, we now know that this sample
size is likely to be too small, by an order of magnitude, to detect
genome-wide signiﬁcant SNPs.31
In summary, general ﬂuid cognitive functioning is a key aspect of
health in older age. It is important to identify the determinants of
its individual differences, both environmental and genetic. To date,
studies have been too small to detect the expected small genetic
effects. Here we conduct a meta-analysis of GWAS studies of
general ﬂuid cognitive functioning in middle and older age from
the Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy (CHARGE) consortium, with a total of 53 949 individuals.
MATERIALS AND METHODS
Participants
This report includes individuals from 31 population-based cohorts partici-
pating in the Cohorts for Heart and Aging Research in Genomic
Epidemiology consortium (Supplementary Table S1 and Supplementary
Information 1 Section 1). All participants were of European ancestry and
aged 45 years or older. Exclusion criteria included prevalent dementia and
clinical stroke (including self-reported stroke). The total sample size was
53 949 individuals (Nmen = 23 030, Nwomen = 30 919).
General ﬂuid cognitive function phenotype
For each of the cohorts, a general ﬂuid cognitive function component
phenotype was constructed from a number of cognitive tasks, each testing
a different cognitive domain. In order to construct this measure, each
cohort was required to have tasks that tested at least three different
cognitive domains. Principal component analysis was applied to the
cognitive task scores to derive a measure of general cognitive function,
which was the score on the ﬁrst unrotated principal component.
Correlations between each test score and the general cognitive function
score were calculated for each cohort, to conﬁrm that all cohorts’ general
cognitive function scores had been scored in the required direction, that is,
with a higher test score indicating higher cognitive function. Further
details of the cognitive tasks undertaken and of the phenotype construc-
tion in each cohort are provided in Supplementary Information 1 Section 2.
In summary, there was a clear single component accounting for between
33.7% and 62.3% (mean=49.6%) of the total cognitive test variance in all
cohorts.
Cohorts used different batteries of cognitive tests, which means that
there will be phenotypic heterogeneity. However, it has been shown that
the individual differences found on the general cognitive component
derived from different cognitive test batteries are very similar.32,33 Here we
give an example of the similarity of the scores obtained when using two
different sets of tests to derive the general cognitive ability component.
This can be illustrated in the Lothian Birth Cohort 1936, because it has such
a large battery of cognitive tests.34 Two general ﬂuid-type cognitive
function component phenotypes could be derived, each using a different
battery of cognitive tests. Of course, only one of these was used in the
GWAS study. The ﬁrst comprised six non-verbal tests from the Wechsler
Adult Intelligence Scale-III UK; these were Block Design, Digit Symbol,
Symbol Search, Letter-Number Sequencing, Backward Digit Span and
Matrix Reasoning. The second contained the Moray House Test, Logical
Memory, Spatial Span, Four Choice Reaction Time and Verbal Fluency.
These two general cognitive function phenotypes calculated from two
non-overlapping batteries of cognitive tests in the Lothian Birth Cohort
1936 had a correlation of r= 0.79 (Po0.001). Thus, we use this as a
methodological illustration to show that there is substantial overlap
between the general ﬂuid cognitive ability components from different sets
of tests.
Genotyping and quality control
Each cohort applied quality control (QC) measures based on SNP and
sample-based missingness, minor allele frequency, Hardy–Weinberg
equilibrium, relatedness and evidence of non-Caucasian descent. Cohort-
speciﬁc thresholds for these QC measures along with details of geno-
typing, imputation methods and reference panels are detailed in
Supplementary Table S2.
Statistical analyses
Genotype–phenotype association analyses. Genotype–phenotype associa-
tion analyses were performed, using an additive model, on imputed SNP
dosage scores within each cohort (Supplementary Figures S1 and S2).
Adjustments for age, sex and population stratiﬁcation, if required, were
included in the model. Cohort-speciﬁc covariates—for example, site or
familial relationships—were also ﬁtted as required. The cohort-speciﬁc
association results were subjected to QC procedures before meta-analysis.
SNPs were excluded based on imputation quality (IMPUTE infoo0.4,
MACH r2o0.3, BIMBAM r2o0.3) and minor allele frequency (o0.5%).
Only SNPs that passed these QC criteria in > 50% of individuals were
included in the meta-analysis (2 478 500 SNPs). A meta-analysis of the 31
cohorts was performed using the METAL package with an inverse variance
weighted model implemented and single genomic control applied (http://
www.sph.umich.edu/csg/abecasis/Metal). SNP-based results were also
compared to published results for educational attainment35 (Social Science
Genetic Association Consortium) and general cognitive function in
childhood36 (Childhood Intelligence Consortium).
Gene-based tests of association were performed using the VEGAS
software.37 In addition, we examined the gene-based ﬁndings for
association with published candidate genes previously associated with
Alzheimer’s disease (AD) or neuropathological features of AD and related
dementias,38–44 educational attainment35 and general cognitive function in
childhood.36
Prediction analyses. In order to perform prediction analyses in Generation
Scotland (GS), a meta-analysis was performed, which excluded this cohort.
A multi-SNP prediction model was created using the proﬁle scoring
method implemented in PLINK.45 This uses the effect sizes estimated in the
meta-analysis. The GS best-guess imputed data were used for this analysis,
an imputation quality threshold of r240.9 was applied, and the remaining
SNPs were pruned to remove those in linkage disequilibrium (based on
r240.25 within a 200-SNP sliding window). The estimated effect sizes from
the meta-analysis for each of these SNPs were then used to calculate a
prediction score for each GS individual. A series of prediction scores was
created based on the inclusion of SNPs with a range of association P-
values: all SNPs and SNPs with Po0.5, Po0.1, Po0.05 or Po0.01. Linear
or logistic regressions of the prediction score and cognitive phenotypes,
and some health outcomes previously associated with cognitive function46
were performed. We calculated the proportion of phenotypic variance that
was predicted by adding the prediction score to a ‘null’ model that
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adjusted for age, sex and population stratiﬁcation (four principal
components). The cognitive phenotypes from GS that were included in
the prediction analysis were general cognitive function, general ﬂuid
cognitive function, Wechsler Digit Symbol Substitution Task,47 Wechsler
Logical Memory Test,48 Verbal Fluency49 and the Mill Hill Vocabulary Scale
(junior+senior synonyms).50 The health outcomes included in the predic-
tion analysis were self-reported cardiovascular disease, type 2 diabetes and
hypertension. Polygenic prediction analyses were also performed in GS for
cognitive phenotypes using published GWAS results for AD39 (International
Genomics of Alzheimer’s Project) and educational attainment.35
Estimation of SNP-based heritability using GCTA analysis. The GCTA
program51 was used to estimate the proportion of variance explained by
all common SNPs for general cognitive function in the Atherosclerosis Risk
in Communities Study (ARIC) and Health and Retirement Study (HRS)
cohorts. These cohorts were selected to be used for this analysis, because
they are two of the largest cohorts in the study. The total numbers of
individuals included in these analyses were 6617 for the ARIC cohort and
5976 for the HRS cohort. These totals differ from the single SNP analyses,
because close relatives were excluded from this analysis. One individual
was excluded from any pair of individuals that had an estimated coefﬁcient
of relatedness of40.025 to ensure that effects due to shared environment
were not included. The same covariates were included in the GCTA
analyses as for the SNP-based association analyses.
Pathway and functional genomic analyses. The following pathway and
functional genomic methods were performed: INRICH52 and Ingenuity
Pathway Analysis (Ingenuity Systems, www.ingenuity.com), and reference
was made to The Genotype-Tissue Expression Portal (http://www.
gtexportal.org), Regulome DB database53 and the Human Brain Transcrip-
tome Project (hbatlas.org).54 Full details are given in Supplementary
Methods.
RESULTS
The SNP-based meta-analysis identiﬁed 13 SNPs associated with
general cognitive function at a genome-wide signiﬁcance level
(Po5 × 10− 8) (Figure 1, Figure 2 and Supplementary Figure S3).
These SNPs were located in three genomic regions, 6q16.1, 14q12
and 19q13.32. The top SNP in each region and genes contained in
the region were, 6q16.1, rs10457441 (P= 3.93 × 10− 9; MIR2113),
14q12, rs17522122 (P= 2.55 × 10− 8; AKAP6/NPAS3) and 19q13.32,
rs10119 (P= 5.67 × 10− 9; TOMM40/APOE) (Figure 2). The effect size
of rs10119 was signiﬁcantly correlated with mean age of the
cohort (r=− 0.424, P= 0.022; Figure 3 and Supplementary
Figure S4). There was no signiﬁcant correlation with cohort age
for the other two SNPs (rs10457441 and rs17522122)
(Supplementary Figures S5 and S6). All 361 SNPs from the meta-
analysis with a P-value less than a suggestive signiﬁcance
threshold of Po1 × 10− 5 are detailed in Supplementary Table S3.
Gene-based tests of association yielded one genome-wide
signiﬁcant result (Po2.8 × 10− 6), for the gene HMGN1
(P= 1× 10− 6) located on chromosome 21. All 184 gene-based
association results with a P-value below the suggestive threshold
(Po1 × 10− 3) are detailed in Supplementary Table S4.
Supplementary Table S5 shows the gene-based association
results for 29 genes previously reported to be associated with AD
or neuropathologic features of AD and related dementias.38–44
Four of these genes, TOMM40, APOE, MEF2C and ABCG1, were
associated with general ﬂuid cognitive function at Po0.01. Owing
to linkage disequilibrium, the association P-values for APOE and
TOMM40 are not independent. APOE and TOMM40 are located in
the region of chromosome 19 identiﬁed by the SNP-based meta-
analysis.
Supplementary Tables S6A and S7A show the top SNP-based
results from published GWAS of educational attainment35 and
general cognitive function in childhood.36 It should be noted that
these are not independent studies due to sample overlap in some
cohorts between the current study and both of these previously
published studies (overlaps are: educational attainment
N~ 30 000; general cognitive function in childhood N~ 1500). Of
the 361 suggestively signiﬁcant SNPs from the current meta-
analysis (Supplementary Table S3), 188 and 192 SNPs demon-
strated nominal signiﬁcance (Po0.05) with the educational
attainment phenotypes of years of education and college
completion, respectively (Supplementary Table S7B). Sixteen SNPs
achieved Po1 × 10− 6 in the educational attainment analyses35;
six of these achieved nominal signiﬁcance in the current meta-
analysis (Supplementary Table S7A). Of the top 100 SNPs in the
general cognitive function in childhood GWAS,36 11 reached a
nominal level of signiﬁcance in the current study (Supplementary
Table S6A). Comparisons of gene-based results are shown in
Supplementary Tables S6B, S7C and S7D. For the educational
attainment phenotypes, 17 and 14 of the top 25 genes associated
with years of education and college completion,35 respectively,
were nominally signiﬁcant in the current gene-based results. For
childhood general cognitive function,36 eight of the top 20 gene-
based ﬁndings achieve nominal signiﬁcance in the current study.
Results from the meta-analysis are consistent with a polygenic
model of inheritance. This is demonstrated by the clear early
deviation from the null hypothesis observed in the QQ plot
(λ= 1.14) (Figure 1). To investigate further whether the general
cognitive phenotype is under polygenic control as is indicated by
the association meta-analyses, we applied the analysis within
the GCTA set of methods51 that estimates the proportion of
phenotypic variance explained by all SNPs in two of the largest
single cohorts: ARIC and HRS. For the ARIC and HRS cohorts,
respectively, the GCTA method returned SNP heritability estimates
of 0.29 (s.e. = 0.05; N= 6617; P= 2.34 × 10− 9) and 0.28 (s.e. = 0.07;
N= 5976; P= 2.00 × 10− 5).
The results from the polygenic prediction analyses are shown in
Supplementary Table S8. The maximum proportion of phenotypic
variance explained in GS using the prediction set derived from the
meta-analysis excluding GS was 1.27% (P= 1.5 × 10− 17) for general
cognitive function when using the Po0.50 SNP set (N= 47 322).
The proportion of variance explained in other cognitive domains
ranged from near-zero values to about 1% (Supplementary Table
S8). The polygenic score did not signiﬁcantly predict cardiovas-
cular disease, hypertension or type 2 diabetes in GS (all P40.01).
Supplementary Table S9 shows the results from the polygenic
prediction using the published results for educational attain-
ment35 (years of education and completion of a college degree)
and AD.39 For educational attainment, the maximum proportion of
phenotypic variance explained in GS for the general cognitive
phenotype was 0.54% (P= 2.78 × 10− 8) when using the Po0.50
SNP set (N= 40 239). For AD, signiﬁcant predictions were observed
for only the more inclusive SNP sets (Po0.50 and Po1) and the
maximum proportion of phenotypic variance explained was
0.19%. Owing to the interdependency of the cognitive function
measures, health outcomes and polygenic scores, no correction
for multiple testing was applied to the P-values presented.
Supplementary Table S10 lists Gene Ontology gene sets that
showed nominal enrichment before correction for multiple testing
in the INRICH analysis. None of the Gene Ontology gene sets
remained signiﬁcant after correction for multiple testing. The
highest ranked 70-node network in the Ingenuity Pathway
Analysis included 58 molecules with CDK2 as a central hub
(Supplementary Figure S7). The second-ranked 70-node network
included 38 molecules and had three multi-connected hubs:
RHOA, NUPR1 and SRF. The highest ranked 140-node network
includes 103 molecules and combines the top two 70-node
networks (Supplementary Figure S8). The top function categories
associated with this network are cell cycle, cell death and survival,
and gene expression. The top canonical pathways were inositol
pyrophosphates biosynthesis, tRNA charging, Ga12/13 signaling,
IL-15 production and role of NFAT in regulation of the immune
response.
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Using the Genotype-Tissue Expression Portal database (http://
www.gtexportal.org), no cis–expression quantitative trait loci
associations were identiﬁed for the 13 genome-wide signi-
ﬁcant SNPs. Supplementary Figure S9 shows differential expres-
sion of the top two genes from the VEGAS analysis, HMGN1 and
BRWD1, in six brain regions over the human lifecourse (http://
hbatlas.org/pages/hbtd). Neither gene demonstrated differential
expression across the brain regions shown in middle and older
age. For this study, data mining of regulatory elements was
restricted to normal brain relevant cell lines/tissues. Supplemen-
tary Table S11 demonstrates evidence of regulatory elements
associated with 7 of the 13 genome-wide signiﬁcant SNPs (http://
www.regulomedb.org/).
DISCUSSION
In this genome-wide association study of general cognitive
function in middle and older age, with a total N of 53 949
participants, we report 13 genome-wide signiﬁcant SNP-based
associations in the three genomic regions 6q16.1, 14q12 and
19q13.32. There was one gene-based signiﬁcant association with
the HMGN1 gene located on chromosome 21. We observed
association of general cognitive function with four genes
previously associated with AD or neuropathological features of
AD and related dementias (TOMM40, APOE, MEF2C and ABCG1).
The results from the meta-analysis are consistent with a polygenic
model of inheritance, indicating that many variants of small effect
contribute to the additive genetic inﬂuences on general cognitive
function. Using GCTA, we present consistent estimates of the
lower bound of the narrow sense heritability of general ﬂuid
cognitive function, 0.29 and 0.28, from two of the largest cohorts
(ARIC and HRS). We are able to predict, using only common SNP
data to create a polygenic score, ~ 1.2% of the variance in general
cognitive function in an independent sample (GS). Pathway and
network analyses did not produce signiﬁcant ﬁndings. None of the
13 SNPs achieving genome-wide signiﬁcance were coding
variants. However, functional annotation provided evidence of
regulatory elements for seven SNPs, suggesting that they might
have a functional non-protein coding effect.
The 19q13.32 region, which includes the APOE ε2/3/4 haplotype
and was associated with general cognitive function in this study,
has previously been associated with cognitive phenotypes in old
age,55–58 AD42,59–61 and non-pathological cognitive aging.28,29
Here we ﬁnd that the APOE/TOMM40 region is also associated with
general cognitive function in middle and older age. The only
published GWAS of general cognitive function in older age, to
date, did not report any signiﬁcant APOE/TOMM40 ﬁndings.30
From the data presented here, it is not possible to identify a single
SNP or gene within this region that is driving the association, as it
is a gene-dense region that is known to exhibit a strong pattern of
linkage disequilibrium. Davies et al.28 performed a ﬁne-mapping
analysis of this region, which indicated that the observed
association with non-pathological cognitive aging was being
driven by APOE-based variation.28 A functional analysis of the
APOE locus, including TOMM40, found that multiple APOE locus
cis-regulatory elements inﬂuence both APOE and TOMM40
promoter activity.62 Functional annotation of the top SNP
(rs10119) in the present study demonstrated evidence of
Figure 1. Manhattan (a) and Q–Q (b) plots of P-values of the association between single-nucleotide polymorphisms (SNPs) and general
cognitive function in the meta-analysis. The threshold for genome-wide signiﬁcance (Po5 × 10− 8) is indicated by the red line and the
threshold for suggestive signiﬁcance (Po1 × 10− 5) is indicated by the blue line.
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regulatory elements, indicating regions of active transcription and
epigenetic modiﬁcation. All of these factors suggest that there is a
complex transcriptional regulatory structure modulating regional
gene expression at the APOE/TOMM40 locus. Drawing on the large
number of cohorts in the present paper, we found a signiﬁcant
correlation between mean cohort age and the effect size of
rs10119 (located in the APOE/TOMM40 region) on general
cognitive function in older age. The effect was near to zero at
younger mean ages and larger at older ages. This might help
toward resolving some of the uncertainty about age moderation
of APOE ε4 status associations with cognitive function that are
based on single studies.63–65
The 14q12 region identiﬁed by the meta-analysis contains both
the AKAP6 and NPAS3 genes. AKAP6 (A kinase (PRKA) anchor
protein 6) is highly expressed in various brain regions, and cardiac
and skeletal muscle. It is speciﬁcally localized to the sarcoplasmic
reticulum and nuclear membrane, and is involved in anchoring
protein kinase A to the nuclear membrane or sarcoplasmic
reticulum.66 SNPs within this gene have tentatively been asso-
ciated with several diseases/traits by GWAS: rs4296166 has been
Figure 2. Regional association plots of genomic regions, which demonstrated genome-wide signiﬁcance (Po5 × 10− 8) in the meta-analysis,
for chromosomes 6 (a), 14 (b) and 19 (c). The circles represent each genotyped single-nucleotide polymorphism (SNP), with the color
indicating pairwise linkage disequilibrium (LD) in relation to the top hit (calculated from 1000 Genomes Nov 2010 EUR); − log10 P-values are
also indicated (y axis). The purple diamond represents the top SNP in each region. The solid blue line indicates the recombination rate.
Figure 3. Plot of effect size against mean age of cohort for rs10119 (top SNP APOE/TOMM40 region). Each numbered point represents a cohort
(1, RSIII; 2, ERF; 3, SPLIT; 4, GS; 5, KORCULA; 6, NCNG; 7, GENOA; 8, ORCADES; 9, RSI; 10, FHS; 11, ASPS; 12, BASEII; 13, BETULA; 14, HCS; 15, RSII;
16, HBCS; 17, LBC1936; 18, HRS; 19, OATS; 20, TASCOG; 21, 3C; 22, PROSPER-Netherlands; 23, ROS; 24, PROSPER-Scotland; 25, PROSPER-Ireland;
26, AGES; 27, LBC1921; 28, CHS; 29, MAP). Two cohorts (ARIC and Sydney MAS) did not have data available for rs10119. Dashed regression line
and shaded 95% conﬁdence interval are shown. For full details of abbreviations, see Supplementary Information 2: Cohort Abbreviations.
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associated with risk of AD at a suggestive level of signiﬁcance,67
rs2383378 was suggestively associated with anorexia nervosa,68
rs2300835 was associated with fasting insulin levels in the
discovery sample of a GWAS of fasting glycemic traits, but failed
to replicate,69 and rs1951681 and rs3784178 were suggestively
associated with economic and political preferences (environment-
alism).70
NPAS3 (neuronal PAS domain protein 3) encodes a member of
the basic helix-loop-helix and PAS domain-containing family of
transcription factors that is expressed in the brain. The encoded
protein is localized to the nucleus and may regulate genes
involved in neurogenesis.71 It has been associated with brain
development and potentially human brain evolution.72 A balanced
reciprocal translocation t(9,14)(q34.2;q13) that disrupts NPAS3 was
identiﬁed in a mother and daughter with schizophrenia and
schizophrenia co-morbid with mild learning disability, respec-
tively.73,74 A GWAS has since reported three coding SNPs
(rs12434716, c.1654G4C, P= 0.009; rs10141940, c.2208C4T,
P= 0.01; and rs10142034, c.2262C4G, P= 0.01) to be associated
with schizophrenia.75
The genome-wide signiﬁcant SNPs in the 6q16.1 region are
located ~ 100 kb downstream of an uncharacterized microRNA
gene MIR2113. This region has been previously associated with
bipolar disorder (rs12202969, P= 1.08 × 10− 8)76 and educational
attainment.35 Evidence of regulatory elements associated with six
of the top SNPs in this region, within normal brain-related tissues
and cell lines, was identiﬁed using the Regulome DB database. The
regulatory elements identiﬁed include histone modiﬁcations,
DNase hypersensitive sites and position weight matrix sites. This
evidence suggests that the associated SNPs are in sites of active
transcription and could have a regulatory role on transcription.
The signiﬁcant ﬁnding from the gene-based analysis, HMGN1
(high mobility group nucleosome-binding domain 1), encodes a
nucleosome-binding protein that is associated with transcription-
ally active chromatin.77 HMGN1 negatively regulates methyl CpG-
binding protein 2 (MeCP2), a DNA-binding protein that is mutated
in the neurodevelopmental disorder Rett syndrome78 and is
known to affect neurological functions including X-linked mental
retardation, various autism spectrum disorders in humans and the
behavior of mice. It is overexpressed in Down syndrome and it has
been suggested that epigenetic changes resulting from altered
HMGN1 levels could have a role in the etiology of several neuro-
developmental disorders including autism and Down syndrome.79
Four of the 29 genes previously reported to be associated with
AD38–42,44 or neuropathological features of AD and related
dementias43 were associated with general cognitive function
(at Po0.01). These were TOMM40, APOE, MEF2C and ABCG1. These
results suggest that there is overlap between the genetic
contribution to ‘normal’ and ‘pathological’ cognitive variation in
older age. A polygenic prediction analysis using a large published
GWAS of AD39 signiﬁcantly predicted only 0.19% of the
phenotypic variation in general cognitive function in GS. However,
Harris et al.80 reported no signiﬁcant association of polygenic
score for AD with general cognitive ability when using smaller
sample sizes for both the creation of the polygenic score and the
prediction analysis. All known cases of clinical dementia were
removed from the contributing cohorts. Of course, some or all of
the effects we found could be driven by the inadvertent inclusion
of individuals in a prodromal stage of dementia, and that we have
picked up the genetic effects on this. This is an important issue
that is impossible to eliminate entirely. Ideally, one would wish to
know, prospectively, which people in the current cohorts
eventually developed dementia and then re-run the analyses
after omitting them. However, some people will die or be lost to
contact before such an assessment could be made, thus prevent-
ing complete ascertainment. On the other hand, it is possible to
envisage a study that tracks individuals and re-analyses those who
have kept in contact and those who do not, say over a 10-year
period, develop dementia. This could clarify whether the effects
we found here were on the normal range of age-related cognitive
change. The present study includes individuals within and beyond
the ninth decade. It is also important to note that the cognitive
phenotype we measured is a composite of people’s stable trait
levels and any age-related change that has occurred. Therefore,
genetic effects might be contributing to either.
The results of this study (SNP and gene-based) were compared
with those of previously published large GWAS of educational
attainment35 and general cognitive function in childhood.36
Before discussing these results further, it should be noted that
there is sample overlap between both of these studies and the
current study (overlaps are: educational attainment, N~ 30 000;
childhood general cognitive function, N~ 1500). Around 50% of
the suggestive SNPs from the current study are nominally
signiﬁcant for educational attainment and the 6q16.1 region is
reported to be genome-wide signiﬁcant for both general cognitive
function and educational attainment. The gene-based ﬁndings
also demonstrated some consistency, with more than half of the
top 25 genes for years of education and college completion
achieving nominal signiﬁcance in the current study. Of the top 100
SNPs for childhood cognitive function, 11 achieved nominal
signiﬁcance in the current study along with eight of the top 20
gene-based ﬁndings. These ﬁndings suggest that there is overlap
between the genetic contribution to general cognitive function in
late-middle and older age, and both educational attainment and
childhood general cognitive function. This has also been explored
in a study, which used education as a proxy phenotype for general
cognitive function.81 The bivariate heritability of educational
attainment and general cognitive function has been previously
estimated in GS using both pedigree-based and SNP-based
methods (biv h2 = 0.78, N~ 20 500 and biv h2 = 0.59, N~ 6600,
respectively).82 The genetic correlation and bivariate heritability of
childhood and older age general cognitive functions have also
been previously estimated in a relatively small sample (N~ 1900),
(rg = 0.62; biv SNP h
2 = 0.21).83
This study provides further evidence that general cognitive
function is heritable and under polygenic control. These ﬁndings
are consistent with, and add considerably to those from the
Cognitive Ageing in Genetics in England and Scotland consor-
tium.30 The early deviation from the expected distribution in the
QQ plot could be indicative of two outcomes; ﬁrst, polygenic
effects and, second, population stratiﬁcation. All of the individual
cohorts applied the required number of principal component
analysis/multidimensional scaling components to their initial
association analyses to adjust for stratiﬁcation that may be
present within the individual cohorts. None of the individual
cohorts demonstrate both an early deviation and an inﬂated λ-
value, which would indicate that stratiﬁcation may be present
(Supplementary Figure S2). Single genomic control was imple-
mented in the meta-analysis. The proportion of phenotypic
variance explained by all SNPs is an estimate of the lower bound
of the narrow sense heritability. The estimates calculated from the
ARIC and HRS cohorts suggest that 29% (s.e. = 0.05) and 28% (s.
e. = 0.07), respectively, of the variation in general cognitive
function can be attributed to common SNPs that are in linkage
disequilibrium with causal variants in these cohorts. Whereas
these estimates are lower than a previously-published estimate
from the Cognitive Ageing in Genetics in England and Scotland
consortium in a smaller sample (51%; s.e. = 0.11; N= 3511),30 they
are slightly higher than an estimate reported from a similar sample
size in GS (21%; s.e. = 0.05; N= 6648).82 To date, these are the only
GCTA-based estimates of the general cognitive function pheno-
type in unrelated early-middle to older age individuals. The
sample-size weighted mean of these estimates is 0.30 (Figure 4). It
should be noted that these four estimates were not based on the
same set of common SNPs, as only directly genotyped SNPs were
included, and that the general cognitive function phenotypes in
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each cohort were constructed using a different set of cognitive
tests. Therefore, the mean of 0.30 is likely to be an underestimate.
Whereas the combined sample size in the present report is a
strength, the results observed here suggest that an even larger
sample size is required in order to seek replication of the ﬁndings
of the present study and to identify more genome-wide signiﬁcant
ﬁndings. For this reason, we chose to present a single discovery
meta-analysis of the largest combined sample available. If general
cognitive function is similar to other complex traits, the individual
effects of common SNPs will be very small. From studies of other
polygenic complex traits, it has been observed that the number of
discovered variants is strongly correlated with experimental
sample size.31 This predicted increase in detectable associations
for complex traits, when sample sizes increase, has been observed
in GWASs of both height—a study of 183 727 individuals reported
180 signiﬁcant associations, of which > 100 were novel loci
compared with previous studies of fewer individuals (No40 000)
—and schizophrenia, in which a study of 21 246 cases and 38 072
controls reported 22 signiﬁcant associations, of which 13 were
novel loci compared with previous studies of fewer individuals
(No18 000 cases).84,85 This is also demonstrated in the present
study when compared with the previously published Cognitive
Ageing in Genetics in England and Scotland consortium study
(N= 3511), which reported no genome-wide signiﬁcant SNP
associations with general cognitive function in older age.30
Phenotypic heterogeneity is a limitation of this study. Each
cohort used a different set of cognitive tests to create the general
cognitive function phenotype. We demonstrated using the
Lothian Birth Cohort 1936 cohort that two general cognitive func-
tion phenotypes calculated in the same set of individuals but
using a different battery of tests for the principal component
analysis are highly (~0.8) but imperfectly correlated. This is con-
sistent with the ﬁnding that general cognitive function pheno-
types derived from different test batteries are highly correlated
and measurement of this phenotype is not dependent on the use
of speciﬁc cognitive tasks.32,33 Given, especially, that a relatively
small number of tests contributed to the general cognitive com-
ponent in some of the cohorts, the heterogeneity of the pheno-
type will be a limitation on the discovery of genetic effects.
In order to dissect the regions of association identiﬁed in the
present study further, deep sequencing of these regions in a larger
sample would be required followed by in-depth functional
genomics studies. This type of approach may elucidate the
mechanisms underlying the observed associations and identify
the causal variants within these associated genomic regions.
In conclusion, we report the largest meta-analysis of GWAS
studies, to date, of ﬂuid general cognitive function in middle and
older age. We also report results showing that general cognitive
function is heritable and highly polygenic, extending ﬁndings of
previous studies involving general cognitive function in older
individuals. We show genome-wide signiﬁcant SNP-based associa-
tions within three genomic regions 6q16.1 (MIR2113), 14q12
(AKAP6/NPAS3 region) and 19q13.32 (TOMM40/APOE region), and a
genome-wide signiﬁcant gene-based association with the HMGN1
gene located on chromosome 21. The 19q13.32 region has long
been associated with AD and more recently was associated with
non-pathological cognitive aging;28 the 6q16.1, 14q12 and HMGN1
regions contain genes associated with development of the
brain,78,79 neurological function,71,72,79 psychiatric disease73–76
and educational attainment.35
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